ClinConnect ClinConnect Logo
Search / Trial NCT00601367

Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder

Launched by SPROUT PHARMACEUTICALS, INC · Jan 25, 2008

Trial Information

Current as of May 27, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Women with a primary diagnosis of HSDD who still needs to be treated according to the investigator's opinion and willing to continue in this study. This continuation requires adequate compliance, in the Investigators judgement, with trial medication and the trial visit required in the parent clinical trial (Visit 1 to visit 9).
  • Patients must have used a medically acceptable method of contraception \[i.e., double barrier method (e.g., diaphragm or condom and spermicide), hormonal therapy (subcutaneous, injectable, intra-vaginal, or oral contraceptive), intrauterine device, tubal sterilization, or partner's surgical sterilization\] for at least 3 months before the Screen Visit and continue to use that medically acceptable method of contraception during the trial.
  • Exclusion Criteria:
  • Patients with a history of MDD within 6 months prior the Screen Visit or a score of 14 on the Beck Depression Inventory II, or a history of suicide attempt according to the Beck Scale for Suicide Ideation, or patient with any non-zero statement in the first five items for the Beck Scale for Suicide Ideation.
  • Patients must have a clinically acceptable Pap smear as read by a cytology facility (no evidence of malignancy or squamous intraepithelial lesions) within 6 months before the Inclusion Visit.
  • Patients with findings at the Screen Visit of pelvic inflammatory disease, urinary tract or vaginal infection/vaginitis, cervicitis, interstitial cystitis, vulvodynia, or significant vaginal atrophy.
  • Patients experiencing major life stress (including parenting pressure, eldercare, loss of income, death of a family member, etc.) or relationship discord that could interfere with sexual activity, except distress about HSDD.
  • Clinically significant ECG abnormalities at the Screen Visit, according to the investigators opinion or the cardiologist who have performed the ECG. The following ECG values are considered to be exclusionary: QTc intervals \>480 milliseconds (ms), PR intervals \>240 ms, and QRS intervals \>110 ms.

About Sprout Pharmaceuticals, Inc

Sprout Pharmaceuticals, Inc. is a leading biopharmaceutical company dedicated to advancing women's health by developing innovative therapies that address unmet medical needs. With a strong focus on scientific research and patient-centered solutions, Sprout is committed to improving the quality of life for women through the discovery and commercialization of safe and effective treatments. The company works collaboratively with healthcare professionals and regulatory bodies to ensure that its products meet the highest standards of safety and efficacy, ultimately empowering women to take control of their health and well-being.

Locations

Innsbruck, , Austria

Wien, , Austria

Wien, , Austria

Wörgl, , Austria

Braine L'alleud, , Belgium

Edegem, , Belgium

Gent, , Belgium

Hasselt, , Belgium

Yvoir, , Belgium

Olomouc, , Czech Republic

Prague, , Czech Republic

Prague, , Czech Republic

Vresina, , Czech Republic

Espoo, , Finland

Helsinki, , Finland

Oulu, , Finland

Seinäjoki, , Finland

Tampere, , Finland

Blanquefort, , France

Bordeaux Cedex, , France

La Rochelle, , France

Lille, , France

Lille, , France

Marseille Cedex 9, , France

Marseille, , France

Marseille, , France

Rennes, , France

Saint Emilion, , France

Toulouse, , France

Berlin, , Germany

Bonn, , Germany

Dresden, , Germany

Frankfurt, , Germany

Freiburg, , Germany

Hannover, , Germany

Leipzig, , Germany

Budapest, , Hungary

Kecskemét, , Hungary

Szeged, , Hungary

Szentes, , Hungary

Catania, , Italy

Pavia, , Italy

Torino, , Italy

Almere, , Netherlands

Amsterdam, , Netherlands

Apeldoorn, , Netherlands

Bilthoven, , Netherlands

Den Helder, , Netherlands

Enschede, , Netherlands

Nieuwegein, , Netherlands

Barcelona, , Spain

Manresa (Barcelona), , Spain

Mataró Barcelona, , Spain

Orense, , Spain

Kungsbacka, , Sweden

Lund, , Sweden

Stockholm, , Sweden

Stockholm, , Sweden

Uppsala, , Sweden

Vasteras, , Sweden

Chorley, , United Kingdom

Fisherwick, Lichfield, , United Kingdom

Glasgow, , United Kingdom

Headington, Oxford, , United Kingdom

London, , United Kingdom

London, , United Kingdom

South Brent, , United Kingdom

Waterloo, Liverpool, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Sprout Pharmaceuticals

Study Chair

Sprout Pharmaceuticals

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials